PMADS

Id:	acc3725
Group:	1sens
Protein:	BAD
Gene Symbol:	BAD
Protein Id:	Q92934
Protein Name:	BAD_HUMAN
PTM:	phosphorylation
Site:	Ser112
Site Sequence:	NLWAAQRYGRELRRMSDEFVD
Disease Category:	Cancer
Disease:	Ovarian Cancer
Disease Subtype:	Tumor Apoptosis
Disease Cellline:	IGROV-1
Disease Info:
Drug:	ST1926+ZD1839
Drug Info:	ST1926 is one of the drugs in the combination \| ZD1839 is the other drug combined with ST1926.
Effect:	modulate
Effect Info:	Combined therapy dephosphorylates the Ser112 site of BAD protein and promotes tumor cell death.
Note:	drug comb
Score:	4.0
Pubmed(PMID):	15781651
Sentence Index:	15781651_5
Sentence:	"Other molecular events induced by the cotreatment included (a) a stabilization of the ST1926-induced genotoxic stress detected by formation of phosphorylated gamma-H2AX foci and (b) a complete inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation associated with activation of the proapoptotic protein BAD (i.e., inhibition of phosphorylation on Ser112)."

Sequence & Structure:

MFQIPEFEPSEQEDSSSAERGLGPSPAGDGPSGSGKHHRQAPGLLWDASHQQEQPTSSSHHGGAGAVEIRSRHSSYPAGTEDDEGMGEEPSPFRGRSRSAPPNLWAAQRYGRELRRMSDEFVDSFKKGLPRPKSAGTATQMRQSSSWTRVFQSWWDRNLGRGSSAPSQ

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

BAD-Ser118
Cancer	Intensity
BRCA	1.02
COAD	0.094
HGSC	-2.688
ccRCC	0.665
GBM	-0.315
HNSC	0.337
LUAD	-0.509
LUSC	0.254
non_ccRCC	0.67
PDAC	0.544
UCEC	-0.072

BAD-Ser134
Cancer	Intensity
BRCA	0.496
COAD	0.025
HGSC	-2.571
ccRCC	0.505
GBM	-0.168
HNSC	-0.14
LUAD	0.142
LUSC	0.308
non_ccRCC	1.623
PDAC	0.07
UCEC	-0.291

BAD-Ser146
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC	0.707
PDAC	-0.707
UCEC

BAD-Ser25
Cancer	Intensity
BRCA	1.201
COAD	0.333
HGSC	-2.06
ccRCC	0.071
GBM	0.221
HNSC	0.141
LUAD	0.314
LUSC	-0.147
non_ccRCC	1.088
PDAC	-1.618
UCEC	0.456

BAD-Ser32
Cancer	Intensity
BRCA
COAD	0.634
HGSC
ccRCC	-0.649
GBM	-0.387
HNSC	-1.466
LUAD	0.675
LUSC
non_ccRCC
PDAC
UCEC	1.193

BAD-Ser34
Cancer	Intensity
BRCA
COAD	0.402
HGSC	-2.657
ccRCC	0.246
GBM	0.244
HNSC
LUAD	0.294
LUSC	0.335
non_ccRCC	0.503
PDAC	0.255
UCEC	0.378

BAD-Ser75
Cancer	Intensity
BRCA
COAD	-0.707
HGSC	0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

BAD-Ser91
Cancer	Intensity
BRCA
COAD
HGSC	0.707
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

BAD-Ser99
Cancer	Intensity
BRCA	0.402
COAD	-1.167
HGSC	1.633
ccRCC	-1.772
GBM	-0.506
HNSC	-0.659
LUAD	-0.029
LUSC	0.613
non_ccRCC	0.977
PDAC	-0.255
UCEC	0.764

BAD-Thr80
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

BAD-Tyr76
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
S	112	U	Acute myeloid leukemia	Phosphorylation	32764981

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb